Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4630-4635

  Chopra, Teena ^a   Marchaim, Dror ^b   Johnson, Paul C ^a   Awali, Reda A ^a   Doshi, Hardik ^a   Chalana, Indu ^a   Davis, Naomi ^a   Zhao, Jing J ^a   Pogue, Jason M ^a   Parmar, Sapna ^a   Kaye, Keith S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ADULT; ADVERSE EFFECTS; AGED; BACTEREMIA; CASE CONTROL STUDY; DRUG EFFECTS; FEMALE; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PARENTERAL NUTRITION; PATHOGENICITY; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; CASE-CONTROL STUDIES; CATHETERS, INDWELLING; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PARENTERAL NUTRITION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84905387417     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02441-14     Document Type: Article

References (32)

1. Towner KJ. 2009. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect. 73:355-363. http://dx.doi.org/10.1016/j.jhin.2009.03.032.
2. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, Rimar D, Almog Y, Gilad J. 2003. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. 54:32-38. http://dx.doi.org/10. 1016/S0195-6701(03)00046-X.
3. Moultrie D, Hawker J, Cole S. 2011. Factors associated with multidrugresistant Acinetobacter transmission: an integrative review of the literature. AORN J. 94:27-36. http://dx.doi.org/10.1016/j.aorn.2010.12.026.
4. Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. 2009. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J. Hosp. Infect. 73:143-150. http://dx.doi.org/10.1016/j.jhin.2009.06.007.
5. Cisneros JM, Rodriguez-Bano J. 2002. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin. Microbiol. Infect. 8:687-693. http://dx.doi.org/10.1046/j.1469-0691.2002.00487. x.
6. Cetin ES, Durmaz R, Tetik T, Otlu B, Kaya S, Caliskan A. 2009. Epidemiologic characterization of nosocomial Acinetobacter baumannii infections in a Turkish university hospital by pulsed-field gel electrophoresis. Am. J. Infect. Contro. 37:56-64. http://dx.doi.org/10.1016/j.ajic.2008.01.010.
7. De AS, Rathi MR, Mathur MM. 2013. Mortality audit of neonatal sepsis secondary to Acinetobacter. J. Glob. Infect. Dis. 5:3-7. http://dx.doi.org/10. 4103/0974-777X.107165.
8. Neonakis IK, Spandidos DA, Petinaki E. 2011. Confronting multidrugresistant Acinetobacter baumannii: a review. Int. J. Antimicrob. Agent. 37:102-109. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.014.
9. Corbella X, Montero A, Pujol M, Dominguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F. 2000. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol. 38:4086-4095.
10. Fierobe L, Lucet JC, Decre D, Muller-Serieys C, Deleuze A, Joly-Guillou ML, Mantz J, Desmonts JM. 2001. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect. Control Hosp. Epidemiol. 22:35-40. http://dx.doi.org/10.1086/501822.
11. Harris AD, Karchmer TB, Carmeli Y, Samore MH. 2001. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32:1055-1061. http://dx.doi.org/10.1086/319600.
12. Paterson DL. 2002. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin. Infect. Dis. 34:1564-1567. http://dx.doi.org/10.1086/340532.
13. Wroblewska MM, Towner KJ, Marchel H, Luczak M. 2007. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland. Clin. Microbiol. Infect. 13:490-496. http://dx.doi.org/10. 1111/j.1469-0691.2007.01694.x.
14. Chen CH, Wu SS, Huang CC. 2013. Two case reports of gastroendoscopyassociated Acinetobacter baumannii bacteremia. World J. Gastroenterol. 19:2835-2840. http://dx.doi.org/10.3748/wjg.v19.i18.2835.
15. Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY. 2005. Predictors of mortality in Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 38:127-136.
16. Garlantézec R, Bourigault C, Boles JM, Prat G, Baron R, Tonnelier JM, Cosse M, Lefevre M, Jourdain S, Lelay G, Daniel L, Virmaux M, Le Du I, Tande D, Renault A, Lejeune B. 2011. Cost-analysis of an intensive care unit closure due to an imipenem-resistant oxa-23 Acinetobacter baumannii outbreak. J. Hosp. Infect. 77:174-175. http://dx.doi.org/10.1016/j.jhin.2010.09.027.
17. Lee BY, McGlone SM, Doi Y, Bailey RR, Harrison LH. 2010. Economic impact of Acinetobacter baumannii infection in the intensive care unit. Infect. Control Hosp. Epidemiol. 31:1087-1089. http://dx.doi.org/10.1086/656378.
18. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Ches. 101:1644-1655.
19. Clinical Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, Ahmed H, Pogue JM, Zhao JJ, Kaye KS. 2013. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob. Agents Chemother. 57:6270-6275. http://dx.doi.org/10.1128/AAC.01520-13.
21. Koeleman JG, Parlevliet GA, Dijkshoorn L, Savelkoul PH, Vandenbroucke-Grauls CM. 1997. Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J. Hosp. Infect. 37:113-123. http://dx.doi.org/10.1016/S0195- 6701(97)90181-X.
22. Lortholary O, Fagon JY, Hoi AB, Slama MA, Pierre J, Giral P, Rosenzweig R, Gutmann L, Safar M, Acar J. 1995. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20:790-796. http://dx.doi.org/10.1093/clinids/20.4.790.
23. Yin T, Chiang MC, Liaw JJ, Kuo SC, Chen TL, Katherine Wang KW. 2012. Clinical characteristics of Acinetobacter baumannii complex bacteremia in patients receiving total parenteral nutrition. J. Chin. Med. Assoc. 75:102-108. http://dx.doi.org/10.1016/j.jcma.2011.12.015.
24. Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Yang SP, Ti Y, Chen TL, Fung CP. 2012. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J. Microbiol. Immunol. Infect. 45:356-362. http://dx.doi.org/10.1016/j.jmii.2011.12.009.
25. Huang L, Chen TL, Lee YT, Lee MH, Kuo SC, Yu KW, Dou HY, Fung CP. 30 April 2013. Risk factors for imipenem-nonsusceptible Acinetobacter nosocomialis bloodstream infection. J. Microbiol. Immunol. Infect. http://dx.doi.org/10.1016/ j.jmii.2013.02.002.
26. Li C, Wen TF, Mi K, Wang C, Yan LN, Li B. 2012. Analysis of infections in the first 3-month after living donor liver transplantation. World J. Gastroenterol. 18:1975-1980. http://dx.doi.org/10.3748/wjg.v18.i16.1975.
27. Avkan-Oguz V, Ozkardesler S, Unek T, Ozbilgin M, Akan M, Firuzan E, Kose H, Astarcioglu I, Karademir S. 2013. Risk factors for early bacterial infections in liver transplantation. Transplant. Proc. 45:993-997. http://dx.doi.org/10. 1016/j.transproceed.2013.02.067.
28. Fukuta Y, Muder RR, Agha ME, Clarke LG, Wagener MM, Hensler AM, Doi Y. 2013. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am. J. Infect. Contro. 41:1249-1252. http://dx.doi.org/10.1016/j.ajic.2013.04.003.
29. Mulin B, Talon D, Viel JF, Vincent C, Leprat R, Thouverez M, Michel-Briand Y. 1995. Risk factors for nosocomial colonization with multiresistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 14:569-576. http://dx.doi.org/10.1007/BF01690727.
30. Scerpella EG, Wanger AR, Armitige L, Anderlini P, Ericsson CD. 1995. Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations. Infect. Control Hosp. Epidemiol. 16:92-97. http://dx.doi.org/10.2307/30140949.
31. Peacock JE, Jr, Sorrell L, Sottile FD, Price LE, Rutala WA. 1988. Nosocomial respiratory tract colonization and infection with aminoglycosideresistant Acinetobacter calcoaceticus var anitratus: epidemiologic characteristics and clinical significance. Infect. Control Hosp. Epidemiol. 9:302-308.
32. Levin AS, Mendes CM, Sinto SI, Sader HS, Scarpitta CR, Rodrigues E, Sauaia N, Boulos M. 1996. An outbreak of multiresistant Acinetobacter baumannii in a university hospital in Sao Paulo, Brazil. Infect. Control Hosp. Epidemiol. 17:366-368. http://dx.doi.org/10.2307/30141136.